2013
Triple-negative breast cancer: molecular characterization and targeted therapies
Nicholson A, Bishop J, Lannin D, Killelea B, Guo X, Cha C, Dixon J. Triple-negative breast cancer: molecular characterization and targeted therapies. Breast Cancer Management 2013, 2: 417-430. DOI: 10.2217/bmt.13.40.Peer-Reviewed Original ResearchBreast cancerTriple-negative breast cancerAggressive breast cancerCancer Genome Atlas NetworkAggressive subtypeSingle therapyClinical trialsTherapeutic targetExtensive molecular characterizationMolecular alterationsIndividual cancersCancerTherapyMolecular targetsMolecular reviewMolecular characterizationRelated mutationsSubtypesTrials
2011
Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens.
Kamalakaran S, Lezon-Geyda K, Varadan V, Banerjee N, Lannin D, Rizack T, Sikov W, Abu-Khalaf M, Janevski A, Harris L. Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens. Journal Of Clinical Oncology 2011, 29: 46-46. DOI: 10.1200/jco.2011.29.27_suppl.46.Peer-Reviewed Original ResearchER/PRVe tumoursCore biopsyHER2 statusER-ve tumoursPreoperative clinical trialHER2 IHC 2Breast core biopsyTissue core biopsyFresh frozen biopsiesPAM50 analysisNab-paclitaxelER statusClinical statusIHC 2Clinical trialsMolecular subtypesPatient tumorsBreast cancer transcriptomeClinical utilityTherapy trialsTumorsMolecular subtypingBiopsyPAM50 classification